Randomised clinical trial comparing sequential and concomitant therapies for <i>Helicobacter pylori</i> eradication in routine clinical practice

Concomitant therapy led to a non-statistically significant advantage (5%) over sequential therapy, coming closer to 90% cure rates. Both therapies showed an acceptable safety profile. ClincialTrials.gov: NCT01273441.